SIRT2 Inhibitor, Inactive Control, AGK7 is a cell-permeable structural isomer of SIRT2(sirtuin 2) Inhibitor, AGK2 (sc-202813) that selectively inhibits SIRT3 over SIRT1 and SIRT2 (IC50 = >5 μM, >50 μM and >50 μM for SIRT3, SIRT1 and SIRT2, respectively). SIRT2 Inhibitor, Inactive Control, AGK7 poorly affects both α-synuclein-mediated toxicity and α-Syn aggregation in α-Syn-H4 cells. SIRT2 Inhibitor, Inactive Control, AGK7 is an inhibitor of SIRT1(sirtuin 1) and SIRT3(sirtuin 3).
What is the recommended dosage of this product for use in human cells in vitro?
Asked by: ChemSynth123
Thank you for your question. SIRT2 Inhibitor, Inactive Control, AGK7 (CAS 304896-21-7): sc-204281 was used in a concentration of 10µM in the paper listed under References on the Description tab. Please note, AGK7 was used on human H4 cells while testing α-Syn-mediated toxicity.
Rated 5 out of
OuteiroOuteiro, TF. et al. (PubMed 17588900) reported that inhibition of SIRT2 via AGK7 rescued alpha-synuclein-mediated toxicity in models of Parkinson's disease. Furthermore, the inhibitor protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn